COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease (GvHD), a life threatening complication of bone marrow transplantation. Prochymal is a proprietary formulation of adult mesenchymal stem cells (MSCs) designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation.
